Report Detail

Request for Sample of this report

Pharma & Healthcare Global Neuroblastoma Treatment Drugs Market Research Report 2022

  • RnM4441029
    • |
  • 18 May, 2022
    • |
  • Global
    • |
  • 94 Pages
    • |
  • QYResearch
    • |
  • Pharma & Healthcare

Summary:

Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
Industry Insights
Due to the COVID-19 pandemic, the global Neuroblastoma Treatment Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Neuroblastoma Treatment Drugs market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Neuroblastoma Treatment Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Cyclophosphamide accounting for % of the Neuroblastoma Treatment Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Neuroblastoma Treatment Drugs include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals. etc. In terms of revenue, the global 3 largest players have a % market share of Neuroblastoma Treatment Drugs in 2021.
This report focuses on Neuroblastoma Treatment Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Neuroblastoma Treatment Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Post-covid-19 Outlook
The readers in the section will understand how the Neuroblastoma Treatment Drugs market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Segmental Outlook
Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).
Segment by Type
Cyclophosphamide
Dinutuximab
Naxitamab
Doxorubicin Hydrochloride
Vincristine Sulfate
Other
Segment by Application
Hospital
Clinic
Other
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Competitive Scenario
In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals
Frequently Asked Questions
Which product segment grabbed the largest share in the Neuroblastoma Treatment Drugs market?
How is the competitive scenario of the Neuroblastoma Treatment Drugs market?
Which are the key factors aiding the Neuroblastoma Treatment Drugs market growth?
Which are the prominent players in the Neuroblastoma Treatment Drugs market?
Which region holds the maximum share in the Neuroblastoma Treatment Drugs market?
What will be the CAGR of the Neuroblastoma Treatment Drugs market during the forecast period?
Which application segment emerged as the leading segment in the Neuroblastoma Treatment Drugs market?
What key trends are likely to emerge in the Neuroblastoma Treatment Drugs market in the coming years?
What will be the Neuroblastoma Treatment Drugs market size by 2028?
Which company held the largest share in the Neuroblastoma Treatment Drugs market?


Table of Contents

    1 Neuroblastoma Treatment Drugs Market Overview

    • 1.1 Product Overview and Scope of Neuroblastoma Treatment Drugs
    • 1.2 Neuroblastoma Treatment Drugs Segment by Type
      • 1.2.1 Global Neuroblastoma Treatment Drugs Sales Growth Rate Comparison by Type (2022-2028)
      • 1.2.2 Cyclophosphamide
      • 1.2.3 Dinutuximab
      • 1.2.4 Naxitamab
      • 1.2.5 Doxorubicin Hydrochloride
      • 1.2.6 Vincristine Sulfate
      • 1.2.7 Other
    • 1.3 Neuroblastoma Treatment Drugs Segment by Application
      • 1.3.1 Global Neuroblastoma Treatment Drugs Sales Comparison by Application: (2022-2028)
      • 1.3.2 Hospital
      • 1.3.3 Clinic
      • 1.3.4 Other
    • 1.4 Global Neuroblastoma Treatment Drugs Market Size Estimates and Forecasts
      • 1.4.1 Global Neuroblastoma Treatment Drugs Revenue 2017-2028
      • 1.4.2 Global Neuroblastoma Treatment Drugs Sales 2017-2028
      • 1.4.3 Neuroblastoma Treatment Drugs Market Size by Region: 2017 Versus 2021 Versus 2028

    2 Neuroblastoma Treatment Drugs Market Competition by Manufacturers

    • 2.1 Global Neuroblastoma Treatment Drugs Sales Market Share by Manufacturers (2017-2022)
    • 2.2 Global Neuroblastoma Treatment Drugs Revenue Market Share by Manufacturers (2017-2022)
    • 2.3 Global Neuroblastoma Treatment Drugs Average Price by Manufacturers (2017-2022)
    • 2.4 Manufacturers Neuroblastoma Treatment Drugs Manufacturing Sites, Area Served, Product Type
    • 2.5 Neuroblastoma Treatment Drugs Market Competitive Situation and Trends
      • 2.5.1 Neuroblastoma Treatment Drugs Market Concentration Rate
      • 2.5.2 The Global Top 5 and Top 10 Largest Neuroblastoma Treatment Drugs Players Market Share by Revenue
      • 2.5.3 Global Neuroblastoma Treatment Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

    3 Neuroblastoma Treatment Drugs Retrospective Market Scenario by Region

    • 3.1 Global Neuroblastoma Treatment Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
    • 3.2 Global Neuroblastoma Treatment Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
    • 3.3 North America Neuroblastoma Treatment Drugs Market Facts & Figures by Country
      • 3.3.1 North America Neuroblastoma Treatment Drugs Sales by Country
      • 3.3.2 North America Neuroblastoma Treatment Drugs Revenue by Country
      • 3.3.3 United States
      • 3.3.4 Canada
    • 3.4 Europe Neuroblastoma Treatment Drugs Market Facts & Figures by Country
      • 3.4.1 Europe Neuroblastoma Treatment Drugs Sales by Country
      • 3.4.2 Europe Neuroblastoma Treatment Drugs Revenue by Country
      • 3.4.3 Germany
      • 3.4.4 France
      • 3.4.5 U.K.
      • 3.4.6 Italy
      • 3.4.7 Russia
    • 3.5 Asia Pacific Neuroblastoma Treatment Drugs Market Facts & Figures by Region
      • 3.5.1 Asia Pacific Neuroblastoma Treatment Drugs Sales by Region
      • 3.5.2 Asia Pacific Neuroblastoma Treatment Drugs Revenue by Region
      • 3.5.3 China
      • 3.5.4 Japan
      • 3.5.5 South Korea
      • 3.5.6 India
      • 3.5.7 Australia
      • 3.5.8 China Taiwan
      • 3.5.9 Indonesia
      • 3.5.10 Thailand
      • 3.5.11 Malaysia
    • 3.6 Latin America Neuroblastoma Treatment Drugs Market Facts & Figures by Country
      • 3.6.1 Latin America Neuroblastoma Treatment Drugs Sales by Country
      • 3.6.2 Latin America Neuroblastoma Treatment Drugs Revenue by Country
      • 3.6.3 Mexico
      • 3.6.4 Brazil
      • 3.6.5 Argentina
      • 3.6.6 Colombia
    • 3.7 Middle East and Africa Neuroblastoma Treatment Drugs Market Facts & Figures by Country
      • 3.7.1 Middle East and Africa Neuroblastoma Treatment Drugs Sales by Country
      • 3.7.2 Middle East and Africa Neuroblastoma Treatment Drugs Revenue by Country
      • 3.7.3 Turkey
      • 3.7.4 Saudi Arabia
      • 3.7.5 UAE

    4 Global Neuroblastoma Treatment Drugs Historic Market Analysis by Type

    • 4.1 Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)
    • 4.2 Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2017-2022)
    • 4.3 Global Neuroblastoma Treatment Drugs Price by Type (2017-2022)

    5 Global Neuroblastoma Treatment Drugs Historic Market Analysis by Application

    • 5.1 Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)
    • 5.2 Global Neuroblastoma Treatment Drugs Revenue Market Share by Application (2017-2022)
    • 5.3 Global Neuroblastoma Treatment Drugs Price by Application (2017-2022)

    6 Key Companies Profiled

    • 6.1 United Therapeutics
      • 6.1.1 United Therapeutics Corporation Information
      • 6.1.2 United Therapeutics Description and Business Overview
      • 6.1.3 United Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.1.4 United Therapeutics Neuroblastoma Treatment Drugs Product Portfolio
      • 6.1.5 United Therapeutics Recent Developments/Updates
    • 6.2 Y-mAbs Therapeutics
      • 6.2.1 Y-mAbs Therapeutics Corporation Information
      • 6.2.2 Y-mAbs Therapeutics Description and Business Overview
      • 6.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.2.4 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product Portfolio
      • 6.2.5 Y-mAbs Therapeutics Recent Developments/Updates
    • 6.3 EUSA Pharma
      • 6.3.1 EUSA Pharma Corporation Information
      • 6.3.2 EUSA Pharma Description and Business Overview
      • 6.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.3.4 EUSA Pharma Neuroblastoma Treatment Drugs Product Portfolio
      • 6.3.5 EUSA Pharma Recent Developments/Updates
    • 6.4 ANI Pharmaceuticals
      • 6.4.1 ANI Pharmaceuticals Corporation Information
      • 6.4.2 ANI Pharmaceuticals Description and Business Overview
      • 6.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolio
      • 6.4.5 ANI Pharmaceuticals Recent Developments/Updates
    • 6.5 Baxter Healthcare
      • 6.5.1 Baxter Healthcare Corporation Information
      • 6.5.2 Baxter Healthcare Description and Business Overview
      • 6.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.5.4 Baxter Healthcare Neuroblastoma Treatment Drugs Product Portfolio
      • 6.5.5 Baxter Healthcare Recent Developments/Updates
    • 6.6 Ingenus Pharmaceuticals
      • 6.6.1 Ingenus Pharmaceuticals Corporation Information
      • 6.6.2 Ingenus Pharmaceuticals Description and Business Overview
      • 6.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.6.4 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolio
      • 6.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
    • 6.7 Pfizer
      • 6.6.1 Pfizer Corporation Information
      • 6.6.2 Pfizer Description and Business Overview
      • 6.6.3 Pfizer Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Pfizer Neuroblastoma Treatment Drugs Product Portfolio
      • 6.7.5 Pfizer Recent Developments/Updates
    • 6.8 Hikma Pharmaceuticals
      • 6.8.1 Hikma Pharmaceuticals Corporation Information
      • 6.8.2 Hikma Pharmaceuticals Description and Business Overview
      • 6.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.8.4 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolio
      • 6.8.5 Hikma Pharmaceuticals Recent Developments/Updates
    • 6.9 Teva Pharmaceuticals
      • 6.9.1 Teva Pharmaceuticals Corporation Information
      • 6.9.2 Teva Pharmaceuticals Description and Business Overview
      • 6.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
      • 6.9.4 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolio
      • 6.9.5 Teva Pharmaceuticals Recent Developments/Updates

    7 Neuroblastoma Treatment Drugs Manufacturing Cost Analysis

    • 7.1 Neuroblastoma Treatment Drugs Key Raw Materials Analysis
      • 7.1.1 Key Raw Materials
      • 7.1.2 Key Suppliers of Raw Materials
    • 7.2 Proportion of Manufacturing Cost Structure
    • 7.3 Manufacturing Process Analysis of Neuroblastoma Treatment Drugs
    • 7.4 Neuroblastoma Treatment Drugs Industrial Chain Analysis

    8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Neuroblastoma Treatment Drugs Distributors List
    • 8.3 Neuroblastoma Treatment Drugs Customers

    9 Neuroblastoma Treatment Drugs Market Dynamics

    • 9.1 Neuroblastoma Treatment Drugs Industry Trends
    • 9.2 Neuroblastoma Treatment Drugs Market Drivers
    • 9.3 Neuroblastoma Treatment Drugs Market Challenges
    • 9.4 Neuroblastoma Treatment Drugs Market Restraints

    10 Global Market Forecast

    • 10.1 Neuroblastoma Treatment Drugs Market Estimates and Projections by Type
      • 10.1.1 Global Forecasted Sales of Neuroblastoma Treatment Drugs by Type (2023-2028)
      • 10.1.2 Global Forecasted Revenue of Neuroblastoma Treatment Drugs by Type (2023-2028)
    • 10.2 Neuroblastoma Treatment Drugs Market Estimates and Projections by Application
      • 10.2.1 Global Forecasted Sales of Neuroblastoma Treatment Drugs by Application (2023-2028)
      • 10.2.2 Global Forecasted Revenue of Neuroblastoma Treatment Drugs by Application (2023-2028)
    • 10.3 Neuroblastoma Treatment Drugs Market Estimates and Projections by Region
      • 10.3.1 Global Forecasted Sales of Neuroblastoma Treatment Drugs by Region (2023-2028)
      • 10.3.2 Global Forecasted Revenue of Neuroblastoma Treatment Drugs by Region (2023-2028)

    11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources
      • 12.3 Author List

      Summary:
      Get latest Market Research Reports on Neuroblastoma Treatment Drugs. Industry analysis & Market Report on Neuroblastoma Treatment Drugs is a syndicated market report, published as Global Neuroblastoma Treatment Drugs Market Research Report 2022. It is complete Research Study and Industry Analysis of Neuroblastoma Treatment Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      		$2,900.00
      		$5,800.00
      		2,328.70
      		4,657.40
      		2,723.10
      		5,446.20
      		448,166.00
      		896,332.00
      		242,382.00
      		484,764.00
      Credit card Logo
      Sample Question Discount Download PDF

      Related Reports

      Reason to Buy

      • Trusted By Leaders

        Top executives from leading companies purchase research reports from us. 

      • Shop With Confidence

        We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

      • Customer Centric

        Need assistance related to your research requirements? We are just a phone call or an email away.

      • Personalized Solutions

        Our experienced research specialists are here to help you locate the right reports for your need.

      • Secure Checkout

        Shop without being worried about safety & security of your transactions.
        •

      Request for Sample of this report

      Reports and Markets

      mcafree

      Contact Us

      +1-352-353-0818 (US)

      info@reportsandmarkets.com

      Support

      EMAIL US

      Newsletter

      KEEP UP TO DATE ON ALL THE LATEST REPORTS


      maxmind_logo